Insider filing · GENB

Noubar Afeyan bought $75.0M of Generate Biomedicines (GENB)

Executed Mar 2, disclosed Mar 2, the same day.

Over the 21 trading sessions from the disclosed entry session (Mar 2), the stock returned -4.2% (delay-adjusted); from the execution session (Mar 2), -4.2%. Derived: entry at the session's open, exit at the close 20 sessions later.

NA Noubar Afeyan Director profile →

Noubar Afeyan (Director) filed 4 Form 4 reports in the trailing twelve months (2 purchases, 2 sales), most often in GENB. Across 2 priced purchase filings, the average 21-session return was -4.2% from execution and -4.2% from disclosure (delay-adjusted; derived). The largest single filing was $75.0M of GENB (4,687,500 sh across 3 lots, as filed), executed Mar 2.

GENB GENB GENB · 3 filings in 24 months ticker → Insider filings, newest first→ View the original filing at www.sec.gov→